Prevalence of ESBLs-producing Pseudomonas Aeruginosa Isolates from Different Wards in a Chinese Teaching Hospital

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2016 Jan 16

PMID 26770582

Citations 12

Authors

Zhilong Chen

Hui Niu

Guangyu Chen

Mingcheng Li

Ming Li

Yuqing Zhou

Affiliations

Soon will be listed here.

Abstract

This study was to explore the molecular dissemination of P. aeruginosa producing extended spectrum β-lactamase (ESBLs) recovered from the different wards in a teaching hospital, Jilin. Among 240 isolates, 91 strains were isolated from burn wards and 149 strains from surgical wards. A total of 210 strains (87.5%) produced ESBLs, 30 strains (12.5%) didn't produce ESBLs. All ESBLs isolates showed identical antimicrobial susceptibility profiles. The genotypic prevalence of ESBLs for bla SHV-12, bla TEM-24, bla CTX-M-1, bla CTX-M-2, bla CTX-M-3, bla PER and bla VEB genes was 17.6%, 20.5%, 14.3%, 9.6%, 12.9%, 13.8% and 11.4% respectively. All P. aeruginosa strains producing ESBLs had three to six plasmids and contained class 1 integrons, which transferred resistance to E. coli C 600 by conjuation. The data indicated a high prevalence of ESBL among P. aeruginosa isolates in this region and their enzyme types were diverse.

Citing Articles

Genetic study of extended spectrum beta-lactamase genes; bla-TEM, blaOXA-10, blaSHV and per-1 in pseudomonas aeruginosa from hospital-acquired infections.

Elmansoury E, Zaki M, Salem M, Montasser K, Hamam S Antonie Van Leeuwenhoek. 2025; 118(4):59.

PMID: 40082286 DOI: 10.1007/s10482-025-02066-z.

Polymerized cyclodextrin microparticles for sustained antibiotic delivery in lung infections.

Bonfield T, Zuckerman S, Sutton M, Korley J, von Recum H J Biomed Mater Res A. 2024; 112(8):1305-1316.

PMID: 38380736 PMC: 11187681. DOI: 10.1002/jbm.a.37680.

Resistance genomics and molecular epidemiology of high-risk clones of ESBL-producing in young children.

Patil S, Chen X, Dong S, Mai H, Lopes B, Liu S Front Cell Infect Microbiol. 2023; 13:1168096.

PMID: 37293207 PMC: 10244630. DOI: 10.3389/fcimb.2023.1168096.

Retrospective analysis of drug resistance characteristics and infection related risk factors of multidrug-resistant organisms (MDROs) isolated from the orthopedics department of a tertiary hospital.

Yang X, Guo R, Zhang B, Xie B, Zhou S, Zhang B Sci Rep. 2023; 13(1):2199.

PMID: 36750600 PMC: 9905492. DOI: 10.1038/s41598-023-28270-3.

Genetic Diversity, Biofilm Formation, and Antibiotic Resistance of Isolated from Cow, Camel, and Mare with Clinical Endometritis.

Mahmoud S, Fayez M, Swelum A, Alswat A, Alkafafy M, Alzahrani O Vet Sci. 2022; 9(5).

PMID: 35622767 PMC: 9147788. DOI: 10.3390/vetsci9050239.

References

Yu Y, Zhou W, Chen Y, Ding Y, Ma Y . Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province. Chin Med J (Engl). 2002; 115(10):1479-82. View

Naas T, Poirel L, Nordmann P . Minor extended-spectrum beta-lactamases. Clin Microbiol Infect. 2007; 14 Suppl 1:42-52. DOI: 10.1111/j.1469-0691.2007.01861.x. View

Lin S, Liu M, Lin C, Shi Z . Phenotypic detection and polymerase chain reaction screening of extended-spectrum β-lactamases produced by Pseudomonas aeruginosa isolates. J Microbiol Immunol Infect. 2012; 45(3):200-7. DOI: 10.1016/j.jmii.2011.11.015. View

Empel J, Filczak K, Mrowka A, Hryniewicz W, Livermore D, Gniadkowski M . Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol. 2007; 45(9):2829-34. PMC: 2045276. DOI: 10.1128/JCM.00997-07. View

Woodford N, Zhang J, Kaufmann M, Yarde S, Tomas M, Faris C . Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom. J Antimicrob Chemother. 2008; 62(6):1265-8. DOI: 10.1093/jac/dkn400. View

Vandijck D, Blot S, Decruyenaere J . Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from patients in a teaching hospital. Jpn J Infect Dis. 2008; 60(6):416. View

Livermore D . Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis. 2002; 34(5):634-40. DOI: 10.1086/338782. View

Leverstein-van Hall M, Paauw A, Box A, Blok H, Verhoef J, Fluit A . Presence of integron-associated resistance in the community is widespread and contributes to multidrug resistance in the hospital. J Clin Microbiol. 2002; 40(8):3038-40. PMC: 120645. DOI: 10.1128/JCM.40.8.3038-3040.2002. View

Cao B, Wang H, Sun H, Zhu Y, Chen M . Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect. 2004; 57(2):112-8. DOI: 10.1016/j.jhin.2004.03.021. View

10.

Weldhagen G, Poirel L, Nordmann P . Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother. 2003; 47(8):2385-92. PMC: 166056. DOI: 10.1128/AAC.47.8.2385-2392.2003. View

11.

Yu Y, Qu T, Zhou J, Wang J, Li H, Walsh T . Integrons containing the VIM-2 metallo-beta-lactamase gene among imipenem-resistant Pseudomonas aeruginosa strains from different Chinese hospitals. J Clin Microbiol. 2006; 44(11):4242-5. PMC: 1698358. DOI: 10.1128/JCM.01558-06. View

12.

Rossolini G, Mantengoli E . Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect. 2005; 11 Suppl 4:17-32. DOI: 10.1111/j.1469-0691.2005.01161.x. View

13.

Bogaerts P, Bauraing C, Deplano A, Glupczynski Y . Emergence and dissemination of BEL-1-producing Pseudomonas aeruginosa isolates in Belgium. Antimicrob Agents Chemother. 2007; 51(4):1584-5. PMC: 1855494. DOI: 10.1128/AAC.01603-06. View

14.

Walsh T, Toleman M, Poirel L, Nordmann P . Metallo-beta-lactamases: the quiet before the storm?. Clin Microbiol Rev. 2005; 18(2):306-25. PMC: 1082798. DOI: 10.1128/CMR.18.2.306-325.2005. View

15.

Goossens H . Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect. 2003; 9(9):980-3. DOI: 10.1046/j.1469-0691.2003.00690.x. View